A Phase 3 interventional study of Tramadol Hydrochloride and Acetaminophen in Pain and Postoperative Pain, sponsored by Janssen Pharmaceutical K.K.. Completed at 12 sites in Japan. Open to participants aged 20 Years to 74 Years. Per ClinicalTrials.gov, last updated 2016-03-31.
Sponsored by Janssen Pharmaceutical K.K. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing tramadol in Pain, Postoperative — 3 open to participants now, 5 under way, none of them phase 3. Tramadol · Pain, Postoperative.
Among the 34 studies testing tramadol in Pain, Postoperative, this one is the 6th largest by enrollment, is the only one that started in 2008, is one of 3 in phase 3, and was the 3rd registered.
5,671 studies on the registry are indexed under Pain, Postoperative; 1,241 are open to participants now.
Browse Pain, Postoperative studies →3 of the 34 studies testing tramadol in Pain, Postoperative are open now, in 3 countries. Recruiting first, the newest first:
Northwestern University · Sites in United States
Ages 18–80
University of Thessaly · Sites in Greece
Ages 18–80
Arzu Esen Tekeli · Sites in Turkey
Ages 18–65
By country, each count listing its studies:
Tramadol: first FDA approval 1995 (ULTRAM). What it is approved for, and how studies give it, is on its page →
Of the 677 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 20 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 5 · Phase 4 16
First in 2002; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 328 is above the median of 75 across 4,850 interventional studies indexed under Pain, Postoperative.
Median enrollment 93 across the 34 interventional studies. Of the 25 that completed or were terminated, 5 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 34 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Pharmaceutical K.K., one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Pharmaceutical K.K. is the lead sponsor of 126 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 7 (50%) have results posted.
18 studies in Pain, Postoperative by Johnson & Johnson: none open now, none under way, none of them phase 3. Of 17 finished, 9 (53%) have results posted.
Among the 18 studies in Pain, Postoperative by Johnson & Johnson, this one is the 8th largest by enrollment, is one of 8 that started in 2008, is one of 8 in phase 3, and was the 6th registered.
Johnson & Johnson’s Pain, Postoperative studies by the year they started, since 2002.
2 of the studies testing tramadol in Pain, Postoperative that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07064993Arzu Esen TekeliEffects of Intraarticular Tramadol and Tramadol-Dexamethasone on Postoperative Pain After Knee Arthroscopy | 2027-02-26 |
| NCT07840183Northwestern UniversityEpidural Analgesia Versus Opioid-sparing Analgesia for Open Ventral Hernia Repair With Transversus Abdominis Release | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 34 studies testing tramadol in Pain, Postoperative, from their registry updates:
Among Johnson & Johnson’s 18 in Pain, Postoperative:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of JNS013 with single oral dose administration in participants with pain after tooth-extraction of mandibular impacted wisdom tooth.
This is a multi-center (conducted in more than one center), double-blind (neither Physician nor participant knows the name of the assigned drug), randomized (study drug assigned by chance), parallel-group (each group of participant will be treated at the same time) and comparative study in participants having pain intensity of at least 50.0 millimeter (mm) (on visual analog scale, score ranging from 0 mm [no pain] to 100 mm [worst possible pain]), following extraction of an impacted mandibular wisdom tooth. The study consists of 3 parts: Pre-observation (7 days before study commences on Day 1); Treatment (Day 1, consists of single oral dosing of either tramadol plus acetaminophen and placebo; or tramadol and placebo; or acetaminophen and placebo) and Follow-up (Day 2 and 8). All the eligible participants will be randomly assigned to 1 of the 3 study treatments. Efficacy of the participants will primarily be evaluated through total pain relief, which will be evaluated on numerical rating scale. Participants' safety will be monitored throughout the study.
5,671 studies on the registry are indexed under Pain, Postoperative; 1,241 are open to participants now.
This study's enrollment of 328 is above the median of 75 across 4,850 interventional studies indexed under Pain, Postoperative.
Browse Pain, Postoperative studies →Janssen Pharmaceutical K.K. is the lead sponsor of 126 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 7 (50%) have results posted.
Compared within Pain, Postoperative, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pain. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tramadol hydrochloride and acetaminophen combination tablet will be administered as single oral dosing of two tablets at a dose of 75 and 650 milligram respectively, along with two oral capsules of matching placebo, within 30 minutes after the intensity of pain associated with tooth extraction showed greater than or equal to (\>=) 50.0 millimeter (mm) on the Visual Analog Scale (VAS), score ranging from 0 mm (no pain) to 100 mm (worst possible pain).
Drug: Placebo · Drug: Tramadol plus Acetaminophen
Tramadol hydrochloride will be administered as single oral dosing of two capsules once at a dose of 75 milligram, along with two oral tablets of matching placebo, within 30 minutes after the intensity of pain associated with tooth extraction showed \>= 50.0 mm on the VAS, score ranging from 0 mm (no pain) to 100 mm (worst possible pain).
Drug: Tramadol Hydrochloride · Drug: Placebo
Acetaminophen will be administered as single oral dosing of two capsules once at a dose of 650 milligram, along with two oral tablets of matching placebo, within 30 minutes after the intensity of pain associated with tooth extraction showed \>= 50.0 mm on the VAS, score ranging from 0 mm (no pain) to 100 mm (worst possible pain).
Drug: Acetaminophen · Drug: Placebo
Tramadol hydrochloride two oral capsules will be administered once as 75 milligram (mg).
Acetaminophen two oral capsules will be administered once as 650 mg.
Two oral tablets or capsules of matching Placebo will be administered once along with Tramadol Hydrochloride and/or acetaminophen.
Drug pages: Tramadol · Acetaminophen
Tramadol hydrochloride and acetaminophen combination tablet will be administered as single oral dosing of two tablets at a dose of 75 and 650 milligram respectively.
Also known as: JNS013
Total Pain Relief Based on Numerical Rating Scale (NRS) Score
Total pain relief was evaluated using numerical rating scale score ranging from 0 to 32, wherein 0 indicates no treatment response and 32 indicates the most improved. Higher score indicates treatment response.
Time frame: 8 hours
Total Pain Relief Based on Numerical Rating Scale (NRS) Score Every 4 Hours up to 8 Hours
Total pain relief was evaluated using numerical rating scale score ranging from 0 to 32, wherein 0 indicates no treatment response and 32 indicates the most improved. Higher score indicates treatment response.
Time frame: Baseline up to 8 hours post-administration of study treatment
Sum of Pain Intensity Difference (SPID)
Pain Intensity (PI) was assessed using numerical rating scale score ranging from 0 to 32, wherein 0 indicates no treatment response and 32 indicates the most improved. Scores were measured at Baseline (that is, 0 hours after tooth extraction) and 8 hours post-administration of study treatments.Pain intensity difference (PID) was calculated (that is, for 0-8 hours, time point \[8 hour\] score minus baseline \[0 hour\] score).
Time frame: Baseline up to 8 hours post-administration of study treatment
Sum of Pain Relief Combined With Pain Intensity Difference (SPRID)
The SPRID is the sum of pain relief scores combined with pain intensity difference, score ranging from from (-) 24 (the worst) through 56 (the most improved). Higher score indicates treatment response. Pain Intensity (PI) and Pain relief (PAR) were assessed using numerical rating scale score ranging from 0 to 32, wherein 0 indicates no treatment response and 32 indicates the most improved. Scores were measured at Baseline (that is, 0 hours after tooth extraction) and at 8 hours post-administration of study treatments. Pain intensity difference (PID) was calculated (that is, for 0-8 hours, time point \[8 hour\] score minus baseline \[0 hour\] score).
Time frame: Baseline up to 8 hours post-administration of study treatment
Change From Baseline in Visual Analog Scale (VAS) Score at 0.5, 1, 2, 3, 4, 5, 6, 7 and 8 Hours Post-administration of Study Treatment
Pain was assessed by using Visual Analogue Scale (VAS) score ranges from 0 millimeter (mm)=no pain to 100 mm=worst possible pain. An increase in score from Baseline represented disease progression and decrease represented treatment response.
Time frame: 0.5, 1, 2, 3, 4, 5, 6, 7 and 8 hours post-administration of study treatment
Mean Change Over Time for Pain Intensity Difference (PID) at 0.5, 1, 2, 3, 4, 5, 6, 7 and 8 Hours Post-Administration of Study Treatment
The PID is defined as difference between current pain intensity (PI) and Baseline PI, PI was assessed using numerical rating scale score ranging from 0 to 32, wherein 0 indicates no treatment response and 32 indicates the most improved. Higher score indicates treatment response. Mean change from Baseline (that is, 0 hours after tooth extraction) at specified end time points were evaluated.
Time frame: 0.5, 1, 2, 3, 4, 5, 6, 7 and 8 hours post-administration of study treatment
Mean Change Over Time for Pain Relief (PAR) at 0.5, 1, 2, 3, 4, 5, 6, 7 and 8 Hours Post-administration of Study Treatment
Pain Relief (PAR) was assessed using numerical rating scale score ranging from 0 to 32, wherein 0 indicates no treatment response and 32 indicates the most improved. Higher score indicates treatment response. Mean change from Baseline (that is, 0 hours after tooth extraction) at specified end time points were evaluated.
Time frame: 0.5, 1, 2, 3, 4, 5, 6, 7 and 8 hours post-administration of study treatment
Mean Change Over Time for Pain Relief Combined With Pain Intensity Difference (PRID) at 0.5, 1, 2, 3, 4, 5, 6, 7 and 8 Hours Post-administration of Study Treatment
Pain Relief combined with pain Intensity Difference (PRID) represented pain relief scores combined with Pain Intensity difference (PID) scores. PRID score ranges from -3 (the worst) through +7 (the most improved). Higher score indicates treatment response. Mean change from Baseline (that is, 0 hours after tooth extraction) at specified end time points were evaluated.
Time frame: 0.5, 1, 2, 3, 4, 5, 6, 7 and 8 hours post-administration of study treatment
Time to Reach the Onset of Drug Efficacy and Time to Recurrence of Pain After the Onset of Drug Efficacy
Time to reach the onset of drug efficacy (TOE) means time took by participants for the onset of relief from pain after tooth-extraction and time to recurrence of pain (TOR) after the onset of drug efficacy (that is, duration of drug efficacy) were assessed after study drug treatment.
Time frame: Baseline up to 8 hours post-administration of study treatment
Percentage of Participants With Categorical Score for Patient Impressions
Percentage of participants with patient impressions were assessed on categories, that are: worked well; worked; worked a little; and didn't work.
Time frame: Baseline up to 8 hours post-administration of study treatment
Number of Participants Treated With a Relief Analgesic
Participants who were treated with a relief analgesic were assessed. Analgesics are the compounds capable of relieving pain without the loss of consciousness.
Time frame: Baseline up to 8 hours post-administration of study treatment
Percentage of Participants With Treatment Response Based on Evaluation Criteria for Efficacy of Analgesics in Post-Tooth-Extraction Pain
Percentage of participants were assessed with treatment response based on "evaluation criteria for efficacy of analgesics in post-tooth-extraction pain" for the efficacy of analgesics used to treat pain following tooth extraction. Participants were assessed as "very effective, effective, somewhat effective and ineffective" for the following categories: Pain suppression (PS), speed of pain relief (SPR), duration of pain relief (DPR), general effectiveness (GE). Participants judged the treatment as "extremely useful, useful, not useful \& could not be assessed" for overall evaluation (OE).
Time frame: Baseline up to 8 hours post-administration of study treatment
| Milestone | Tramadol Hydrochloride Plus Acetaminophen and Placebo | Tramadol Hydrochloride and Placebo | Acetaminophen and Placebo |
|---|---|---|---|
| Started | 132 | 66 | 130 |
| Completed | 129 | 60 | 126 |
| Not completed | 3 | 6 | 4 |
| Withdrew: Physician decision | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 | 0 |
| Withdrew: Worsening of the symptoms | 3 | 5 | 3 |
Total pain relief was evaluated using numerical rating scale score ranging from 0 to 32, wherein 0 indicates no treatment response and 32 indicates the most improved. Higher score indicates treatment response.
| Units on a scale | Tramadol Hydrochloride Plus Acetaminophen and Placebo | Tramadol Hydrochloride and Placebo | Acetaminophen and Placebo |
|---|---|---|---|
| Total Pain Relief Based on Numerical Rating Scale (NRS) Score | 17.7 ± 7.91 | 12.4 ± 8.36 | 13.3 ± 8.07 |
Total pain relief was evaluated using numerical rating scale score ranging from 0 to 32, wherein 0 indicates no treatment response and 32 indicates the most improved. Higher score indicates treatment response.
| Units on a scale | Tramadol Hydrochloride Plus Acetaminophen and Placebo | Tramadol Hydrochloride and Placebo | Acetaminophen and Placebo |
|---|---|---|---|
| 0-4 hours | 9.6 ± 3.90 | 6.3 ± 4.11 | 7.4 ± 3.97 |
| 4-8 hours | 8.0 ± 4.73 | 6.1 ± 4.67 | 5.9 ± 4.71 |
Pain Intensity (PI) was assessed using numerical rating scale score ranging from 0 to 32, wherein 0 indicates no treatment response and 32 indicates the most improved. Scores were measured at Baseline (that is, 0 hours after tooth extraction) and 8 hours post-administration of study treatments.Pain intensity difference (PID) was calculated (that is, for 0-8 hours, time point \[8 hour\] score minus baseline \[0 hour\] score).
| Units on a scale | Tramadol Hydrochloride Plus Acetaminophen and Placebo | Tramadol Hydrochloride and Placebo | Acetaminophen and Placebo |
|---|---|---|---|
| Sum of Pain Intensity Difference (SPID) | 6.4 ± 5.90 | 2.9 ± 5.12 | 4.1 ± 5.84 |
The SPRID is the sum of pain relief scores combined with pain intensity difference, score ranging from from (-) 24 (the worst) through 56 (the most improved). Higher score indicates treatment response. Pain Intensity (PI) and Pain relief (PAR) were assessed using numerical rating scale score ranging from 0 to 32, wherein 0 indicates no treatment response and 32 indicates the most improved. Scores were measured at Baseline (that is, 0 hours after tooth extraction) and at 8 hours post-administration of study treatments. Pain intensity difference (PID) was calculated (that is, for 0-8 hours, time point \[8 hour\] score minus baseline \[0 hour\] score).
| Units on a scale | Tramadol Hydrochloride Plus Acetaminophen and Placebo | Tramadol Hydrochloride and Placebo | Acetaminophen and Placebo |
|---|---|---|---|
| Sum of Pain Relief Combined With Pain Intensity Difference (SPRID) | 24.0 ± 13.03 | 15.3 ± 12.43 | 17.4 ± 13.17 |
Pain was assessed by using Visual Analogue Scale (VAS) score ranges from 0 millimeter (mm)=no pain to 100 mm=worst possible pain. An increase in score from Baseline represented disease progression and decrease represented treatment response.
| Units on a scale | Tramadol Hydrochloride Plus Acetaminophen and Placebo | Tramadol Hydrochloride and Placebo | Acetaminophen and Placebo |
|---|---|---|---|
| Change at Hour 0.5 | -22.11 ± 23.466 | -4.28 ± 20.001 | -15.50 ± 22.336 |
| Change at Hour 1 | -36.79 ± 23.603 | -12.82 ± 27.372 | -26.68 ± 24.570 |
| Change at Hour 2 | -42.71 ± 23.631 | -20.94 ± 27.904 | -28.43 ± 27.583 |
| Change at Hour 3 | -41.40 ± 26.707 | -25.75 ± 28.509 | -28.40 ± 30.544 |
| Change at Hour 4 | -37.70 ± 27.266 | -21.75 ± 29.870 | -24.83 ± 30.753 |
| Change at Hour 5 | -34.78 ± 28.173 | -17.56 ± 29.110 | -21.48 ± 31.350 |
| Change at Hour 6 | -30.20 ± 30.932 | -15.70 ± 31.033 | -17.51 ± 31.875 |
| Change at Hour 7 | -26.37 ± 32.456 | -13.18 ± 30.335 | -15.62 ± 32.562 |
| Change at Hour 8 | -22.85 ± 33.116 | -13.03 ± 30.916 | -14.48 ± 32.638 |
The PID is defined as difference between current pain intensity (PI) and Baseline PI, PI was assessed using numerical rating scale score ranging from 0 to 32, wherein 0 indicates no treatment response and 32 indicates the most improved. Higher score indicates treatment response. Mean change from Baseline (that is, 0 hours after tooth extraction) at specified end time points were evaluated.
| Units on a scale | Tramadol Hydrochloride Plus Acetaminophen and Placebo | Tramadol Hydrochloride and Placebo | Acetaminophen and Placebo |
|---|---|---|---|
| PID:Change at Hour 0.5 | 0.6 ± 0.67 | 0.1 ± 0.55 | 0.5 ± 0.73 |
| PID:Change at Hour 1 | 0.9 ± 0.71 | 0.4 ± 0.70 | 0.7 ± 0.72 |
| PID:Change at Hour 2 | 1.1 ± 0.78 | 0.5 ± 0.71 | 0.8 ± 0.79 |
| PID:Change at Hour 3 | 1.1 ± 0.87 | 0.5 ± 0.73 | 0.7 ± 0.84 |
| PID:Change at Hour 4 | 0.9 ± 0.85 | 0.4 ± 0.70 | 0.6 ± 0.84 |
| PID:Change at Hour 5 | 0.8 ± 0.85 | 0.3 ± 0.73 | 0.5 ± 0.88 |
| PID:Change at Hour 6 | 0.7 ± 0.88 | 0.4 ± 0.80 | 0.4 ± 0.88 |
| PID:Change at Hour 7 | 0.6 ± 0.92 | 0.2 ± 0.77 | 0.3 ± 0.93 |
| PID:Change at Hour 8 | 0.5 ± 0.94 | 0.2 ± 0.77 | 0.3 ± 0.91 |
Pain Relief (PAR) was assessed using numerical rating scale score ranging from 0 to 32, wherein 0 indicates no treatment response and 32 indicates the most improved. Higher score indicates treatment response. Mean change from Baseline (that is, 0 hours after tooth extraction) at specified end time points were evaluated.
| Units on a scale | Tramadol Hydrochloride Plus Acetaminophen and Placebo | Tramadol Hydrochloride and Placebo | Acetaminophen and Placebo |
|---|---|---|---|
| PAR:Change at Hour 0.5 | 1.5 ± 1.12 | 0.7 ± 0.86 | 1.3 ± 0.99 |
| PAR:Change at Hour 1 | 2.3 ± 1.08 | 1.4 ± 1.13 | 2.0 ± 1.11 |
| PAR:Change at Hour 2 | 2.7 ± 1.06 | 1.7 ± 1.23 | 2.0 ± 1.18 |
| PAR:Change at Hour 3 | 2.6 ± 1.18 | 1.9 ± 1.20 | 2.0 ± 1.21 |
| PAR:Change at Hour 4 | 2.4 ± 1.22 | 1.7 ± 1.18 | 1.8 ± 1.20 |
| PAR:Change at Hour 5 | 2.2 ± 1.21 | 1.6 ± 1.16 | 1.6 ± 1.27 |
| PAR:Change at Hour 6 | 2.1 ± 1.20 | 1.6 ± 1.28 | 1.5 ± 1.25 |
| PAR:Change at Hour 7 | 1.9 ± 1.30 | 1.5 ± 1.19 | 1.4 ± 1.27 |
| PAR:Change at Hour 8 | 1.8 ± 1.30 | 1.5 ± 1.15 | 1.4 ± 1.25 |
Pain Relief combined with pain Intensity Difference (PRID) represented pain relief scores combined with Pain Intensity difference (PID) scores. PRID score ranges from -3 (the worst) through +7 (the most improved). Higher score indicates treatment response. Mean change from Baseline (that is, 0 hours after tooth extraction) at specified end time points were evaluated.
| Units on a scale | Tramadol Hydrochloride Plus Acetaminophen and Placebo | Tramadol Hydrochloride and Placebo | Acetaminophen and Placebo |
|---|---|---|---|
| PRID:Change at Hour 0.5 | 2.1 ± 1.67 | 0.8 ± 1.29 | 1.8 ± 1.61 |
| PRID:Change at Hour 1 | 3.2 ± 1.68 | 1.8 ± 1.71 | 2.7 ± 1.69 |
| PRID:Change at Hour 2 | 3.8 ± 1.71 | 2.2 ± 1.80 | 2.8 ± 1.85 |
| PRID:Change at Hour 3 | 3.7 ± 1.92 | 2.4 ± 1.75 | 2.7 ± 1.92 |
| PRID:Change at Hour 4 | 3.3 ± 1.95 | 2.1 ± 1.71 | 2.4 ± 1.92 |
| PRID:Change at Hour 5 | 3.0 ± 1.93 | 1.9 ± 1.74 | 2.1 ± 2.03 |
| PRID:Change at Hour 6 | 2.8 ± 1.96 | 1.9 ± 1.92 | 1.8 ± 2.00 |
| PRID:Change at Hour 7 | 2.5 ± 2.12 | 1.7 ± 1.81 | 1.8 ± 2.08 |
| PRID:Change at Hour 8 | 2.3 ± 2.12 | 1.7 ± 1.78 | 1.6 ± 2.04 |
Time to reach the onset of drug efficacy (TOE) means time took by participants for the onset of relief from pain after tooth-extraction and time to recurrence of pain (TOR) after the onset of drug efficacy (that is, duration of drug efficacy) were assessed after study drug treatment.
| Minutes | Tramadol Hydrochloride Plus Acetaminophen and Placebo | Tramadol Hydrochloride and Placebo | Acetaminophen and Placebo |
|---|---|---|---|
| TOE (n=102, 36, 104) | 47.6 ± 40.88 | 82.8 ± 82.88 | 53.5 ± 47.97 |
| TOR (n=41, 14, 53) | 252.5 ± 119.03 | 207.9 ± 126.44 | 198.2 ± 120.24 |
Percentage of participants with patient impressions were assessed on categories, that are: worked well; worked; worked a little; and didn't work.
| Percentage of participants | Tramadol Hydrochloride Plus Acetaminophen and Placebo | Tramadol Hydrochloride and Placebo | Acetaminophen and Placebo |
|---|---|---|---|
| Worked well | 28.7 ± 10 | 16.4 ± 12.43 | 15.7 ± 13.17 |
| Worked | 55.8 ± 6.29 | 44.3 ± 6.04 | 53.5 ± 6.39 |
| Worked a little | 13.2 ± 7.73 | 24.6 ± 7.04 | 22.8 ± 7.69 |
| Didn't work | 2.3 | 14.8 | 7.9 |
Participants who were treated with a relief analgesic were assessed. Analgesics are the compounds capable of relieving pain without the loss of consciousness.
| Participants | Tramadol Hydrochloride Plus Acetaminophen and Placebo | Tramadol Hydrochloride and Placebo | Acetaminophen and Placebo |
|---|---|---|---|
| Number of Participants Treated With a Relief Analgesic | 37 | 25 | 54 |
Percentage of participants were assessed with treatment response based on "evaluation criteria for efficacy of analgesics in post-tooth-extraction pain" for the efficacy of analgesics used to treat pain following tooth extraction. Participants were assessed as "very effective, effective, somewhat effective and ineffective" for the following categories: Pain suppression (PS), speed of pain relief (SPR), duration of pain relief (DPR), general effectiveness (GE). Participants judged the treatment as "extremely useful, useful, not useful \& could not be assessed" for overall evaluation (OE).
| Percentage of participants | Tramadol Hydrochloride Plus Acetaminophen and Placebo | Tramadol Hydrochloride and Placebo | Acetaminophen and Placebo |
|---|---|---|---|
| PS:very effective (n=107, 46, 113) | 19.4 | 8.2 | 9.6 |
| PS:effective (n=107, 46, 113) | 2.8 | 0 | 0 |
| PS:somewhat effective (n=107, 46, 113) | 63.9 | 42.9 | 67.5 |
| PS:ineffective (n=107, 46, 113) | 13.9 | 49.0 | 22.8 |
| SPR:very effective (n=107, 46, 113) | 56.9 | 21.6 | 44.8 |
| SPR:effective (n=107, 46, 113) | 26.6 | 21.6 | 28.4 |
| SPR:somewhat effective (n=107, 46, 113) | 7.3 | 15.7 | 10.3 |
| SPR:ineffective (n=107, 46, 113) | 9.2 | 41.2 | 16.4 |
| DPR:very effective (n=41, 14, 53) | 39.0 | 28.6 | 24.5 |
| DPR:effective (n=41, 14, 53) | 26.8 | 35.7 | 28.3 |
| DPR:somewhat effective (n=41, 14, 53) | 17.1 | 7.1 | 20.8 |
| DPR:ineffective (n=41, 14, 53) | 17.1 | 28.6 | 26.4 |
| GE:very effective (n=107, 46, 113) | 2.8 | 0 | 0 |
| GE:effective (n=107, 46, 113) | 33.9 | 13.7 | 23.3 |
| GE:somewhat effective (n=107, 46, 113) | 46.8 | 31.4 | 53.4 |
| GE:ineffective (n=107, 46, 113) | 16.5 | 54.9 | 23.3 |
| OE:Extremely useful (n=107, 46, 113) | 0.9 | 0 | 0 |
| OE:useful (n=107, 46, 113) | 11.9 | 3.9 | 17.2 |
| OE:not useful (n=107, 46, 113) | 87.2 | 96.1 | 82.8 |
| OE:could not be assessed (n=107, 46, 113) | 0 | 0 | 0 |
Collected over Baseline up to Day 8. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tramadol Hydrochloride Plus Acetaminophen and Placebo | — | 0/132 (0%) | 82/132 (62.1%) |
| Tramadol Hydrochloride and Placebo | — | 0/66 (0%) | 40/66 (60.6%) |
| Acetaminophen and Placebo | — | 1/130 (0.8%) | 52/130 (40%) |
| Event | Tramadol Hydrochloride Plus Acetaminophen and Placebo | Tramadol Hydrochloride and Placebo | Acetaminophen and Placebo |
|---|---|---|---|
| Drug hypersensitivityImmune system disorders | 0/132 | 0/66 | 1/130 |
| Event | Tramadol Hydrochloride Plus Acetaminophen and Placebo | Tramadol Hydrochloride and Placebo | Acetaminophen and Placebo |
|---|---|---|---|
| SomnolenceNervous system disorders | 39/132 | 15/66 | 14/130 |
| NauseaGastrointestinal disorders | 20/132 | 10/66 | 4/130 |
| DizzinessNervous system disorders | 12/132 | 5/66 | 0/130 |
| Blood bilirubin increasedInvestigations | 12/132 | 6/66 | 11/130 |
| Alveolar osteitisInfections and infestations | 6/132 | 1/66 | 10/130 |
| HeadacheNervous system disorders | 7/132 | 5/66 | 4/130 |
| VomitingGastrointestinal disorders | 10/132 | 2/66 | 1/130 |
| Feeling abnormalGeneral disorders | 4/132 | 5/66 | 1/130 |
| DiarrhoeaGastrointestinal disorders | 1/132 | 0/66 | 4/130 |
| Stomach discomfortGastrointestinal disorders | 4/132 | 0/66 | 0/130 |
| Age, Continuous(Years) | Tramadol Hydrochloride Plus Acetaminophen and Placebo | Tramadol Hydrochloride and Placebo | Acetaminophen and Placebo | Total |
|---|---|---|---|---|
| Mean | 28.1 ± 8.3 | 27.8 ± 8.6 | 27.5 ± 8.2 | 27.8 ± 8.3 |
| Sex: Female, Male(Participants) | Tramadol Hydrochloride Plus Acetaminophen and Placebo | Tramadol Hydrochloride and Placebo | Acetaminophen and Placebo | Total |
|---|---|---|---|---|
| Female | 61 | 32 | 66 | 159 |
| Male | 71 | 34 | 64 | 169 |
| Visual Analog Scale (VAS) Score(Units on a scale) | Tramadol Hydrochloride Plus Acetaminophen and Placebo | Tramadol Hydrochloride and Placebo | Acetaminophen and Placebo | Total |
|---|---|---|---|---|
| Mean | 62.28 ± 9.85 | 60.33 ± 7.63 | 61.32 ± 8.81 | 61.51 ± 9.04 |
The record gives a start of Mar 2008, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2013, 4 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tramadol · Acetaminophen